<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1486">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01908400</url>
  </required_header>
  <id_info>
    <org_study_id>CSCC/BMMR/2013//01</org_study_id>
    <nct_id>NCT01908400</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Mesenchymal Stem Cell in Patients With Mental Retardation</brief_title>
  <official_title>An Open Labeled Clinical Study to Evaluate the Safety and Efficacy of Bone Marrow Derived Mesenchymal Stem Cell in Patients With Mental Retardation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chaitanya Hospital, Pune</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chaitanya Hospital, Pune</source>
  <oversight_info>
    <authority>India: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mental retardation is a condition diagnosed before age 18 that includes below-average
      general intellectual function, and a lack of the skills necessary for daily living. Mental
      retardation affects about 1 - 3% of the population. There are many causes of mental
      retardation, but find a specific reason in only 25% of cases.Bone marrow derived stem cells
      are used in this condition to prove its safety and efficacy .
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Binet-Kamat Test</measure>
    <time_frame>1 YEAR</time_frame>
    <safety_issue>No</safety_issue>
    <description>CHANGE in IQ as measured by Binet-Kamat Test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vineland Social Maturity Scale</measure>
    <time_frame>baseline and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>CHANGE in Social Quotient as measured by Vineland Social Maturity Scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Mental Retardation</condition>
  <arm_group>
    <arm_group_label>Mesenchymal stem cell</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intravenous transfer of Mesenchymal Stem Cell ( MSCs )</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intravenous transfer of Mesenchymal Stem Cell ( MSCs )</intervention_name>
    <description>Intervention therapy , Total 6 doses ,in 30 days ,in 7days interval Intravenous transfer of Bone marrow derived Mesenchymal Stem Cell ( MSCs )</description>
    <arm_group_label>Mesenchymal stem cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age limit: 5 -50

          -  Primary diagnosis of mental retardation (IQ &lt; 70)

          -  willingness to undergo Bone marrow and umbilical cord derived Mesenchymal stem cell
             transplantation.

          -  To give an informed consent as well as sign the required Informed Consent Form
             (ICF)/video Consent for the study.

          -  willingness to regularly visit the hospital / clinic for follow up during the follow
             up period / on prior agreed time points as per the protocol.

        Exclusion Criteria:

          -  Positive test results for HIV and AIDS complex ,HCV (hepatitis C virus ), HbsAg and
             Syphilis

          -  Advanced age that may produce deteriorating cognitive or motor functioning

          -  Multiple sensory or motor disabilities that will interfere with seeing the stimuli
             and responding to the computer

          -  Poor general health
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ANANT E BAGUL, MS ORTHO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chaitanya Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sachin P Jamadar, D.Ortho</last_name>
    <phone>918888788880</phone>
    <email>sac2751982@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Smita S Bhoyar, B.A.M.S.PGCR</last_name>
    <phone>9372620569</phone>
    <email>drsmitabhoyar@rediff.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chaitanya Hospital</name>
      <address>
        <city>Pune,</city>
        <state>Maharashtra</state>
        <zip>411030</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sachin P Jamadar, D ORTHO</last_name>
      <phone>+918888788880</phone>
      <email>sac2751982@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Anant E Bagul, MS,Ortho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 8, 2013</lastchanged_date>
  <firstreceived_date>July 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chaitanya Hospital, Pune</investigator_affiliation>
    <investigator_full_name>Dr. Sachin Jamadar</investigator_full_name>
    <investigator_title>Co -investigator</investigator_title>
  </responsible_party>
  <keyword>Mental retardation ,Mesenchymal stem cell,</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mental Retardation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
